NCT03074513: Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors

NCT03074513
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Active, not recruiting
Phase 2
Drug Category: Immunotherapy, Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Breast cancer patients with neuroendocrine tumors are eligible for cohort 6 (extrapancreatic neuroendocrine basket)
Exclusions: 
https://ClinicalTrials.gov/show/NCT03074513

Comments are closed.

Up ↑